#2700 e 14 blood island skin

Controls were excluded when they had an intraocular melanoma or skin cancer in their history. Eye conditions are not usually associated with skin conditions. Controls ( n = 386) from the same age range and the same referral area were recruited at the LUMC Ophthalmology outpatient clinic. The melanoma cases had no known metastases and did not use any systemic treatment for malignant melanoma. In short, 580 newly diagnosed cases from 1985 to 1997 with histologically confirmed skin cancer were studied: 161 persons with SCC 301 persons with nBCC 153 persons with sBCC and 125 persons with malignant melanoma. The local medical ethical commission approved of the study, and its design was extensively described by De Hertog et al. The study described in this paper is embedded in the Leiden Skin Cancer Study that was initiated at the LUMC in 1997 as a case-control study of the causes of skin cancer in the Dutch population (13). Taken together, our results indicate that EV-HPV serorecognition is nonspecifically associated with nonmelanoma skin cancer and suggest that EV-HPV-directed seroresponses are induced upon skin cancer formation, rather than upon infection. Restricted analyses among patients with skin cancer only, however, revealed that EV-HPV seropositivity was not significantly more present in patients with nonmelanoma skin cancer than in those with melanoma skin cancer. Restricted analyses among the HPV seropositives only, to exclude distortion by interindividual differences in seroresponsiveness, underscored the significance of our findings. The relative risk of developing malignant melanoma was not increased among HPV seropositives, and no associations were found for HPV16. The estimated relative risk for nodular and superficial multifocal basal cell carcinoma was also significantly increased in the HPV8 seropositives and in the HPV20 seropositives. After adjusting for age and sex, the estimated squamous cell carcinoma relative risk was significantly increased in HPV8 and HPV38 seropositives. Seroreactivity to five of the six EV-HPV types tested (HPV5, 8, 15, 20, and 24) was significantly increased in the squamous cell carcinoma cases. By measuring seroreactivity to L1 virus-like particles of EV-HPV types 5, 8, 15, 20, 24, and 38 and the genital type HPV16 and by estimating the skin cancer relative risk among HPV seropositives, we analyzed whether EV-HPV serorecognition is associated with nonmelanoma skin cancer. We designed a case-control study in which we looked for HPV infection in 540 cases with a history of skin cancer and 333 controls. Epidemiological studies that investigate the relation between EV-HPV infection and nonmelanoma skin cancer are scarce. DNA from epidermodysplasia verruciformis-related human papillomavirus (EV-HPV) types is frequently found in nonmelanoma skin cancer (squamous and basal cell carcinoma).

2700 e 14 blood island